Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in treatment of cancer. The license involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals' drug candidate ANXV. Studies have shown that Annexin A5 acts as a potent immunomodulating anti-cancer agent acting via blocking phosphatidylserine (PS) on cancer cells (US patent No 11,253,568).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.285 SEK | -2.73% | -7.47% | +9.62% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.62% | 9.39M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Signs Exclusive Licensing Deal in Cancer